Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
517 people get OPTR articles and Market Currents by email alert.
Get email alerts on OPTR »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 9, 2013)
-
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Mar 15, 2013)
-
PR Newswire (Feb 28, 2013)
-
PR Newswire (Feb 27, 2013)
-
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Feb 1, 2013)
-
-
PR Newswire (Jan 7, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
Optimer Pharmaceuticals' Encouraging FDA NewsZacks Investment Research • Tue, Jul 5, 2011 -
-
-
-
-
-
Promising Year Ahead for Optimer PharmaZacks Investment Research • Mon, Jun 29, 2009
-
-
-
-
-
-
-
-
-
-
-
-
-
Fund Holdings For 3 Healthcare Stocks, And 4 Other SellsGuruFundPicks • Mon, Jun 18, 2012
-
-
-
-
-
9 Rallying Biotech Stocks Being Snapped Up By Hedge FundsKapitall • Tue, May 15, 2012
-
-
5 Hedge Fund Biotech Stock Picks With Significant Short CoveringKapitall • Tue, Apr 24, 2012
-
-
Optimer Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptWed, Mar 11, 2009
-
Optimer Pharmaceuticals, Inc. Q4 2007 Earnings Call TranscriptSun, Apr 27, 2008
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (Apr 26, 2013)
-
PR Newswire (Mar 15, 2013)
-
PR Newswire (Feb 28, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Feb 1, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Dec 24, 2012)
-
PR Newswire (Dec 20, 2012)
-
PR Newswire (Dec 5, 2012)
-
PR Newswire (Nov 7, 2012)
-
PR Newswire (Nov 1, 2012)
OPTR vs. ETF Alternatives
Company Description
Currently, there's no company description for OPTR.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 15, 4:01 PM Shares of Optimer Pharmaceutical (OPTR +15%) spike into the close on rumors that Cubist Pharmaceutical (CBST -0.5%) lobbed a $1B bid for OPTR prior to the sales process. Comment! [Healthcare, M&A, On the Move]
- Monday, May 13, 5:09 PM Shares of Optimer Pharmaceutical (OPTR +14%) ramped up into the close on reports that AstraZeneca (AZN), Astellas Pharma (ALPMY.PK) and Cubist Pharmaceuticals (CBST) are among the first round bidders for the antibiotic manufacturer. OPTR disclosed almost three months ago that they were working with Centerview Partners and JPMorgan to explore its strategic options, including a potential sale. Comment! [Healthcare, On the Move, M&A]
- Friday, May 10, 1:32 PM The sell-off in Optimer Pharmaceuticals (OPTR -16.6%) accelerates as the session drags on, with losses now well into the double-digits. On top of Needham's downgrade (disappointing Dificid sales may equate to less value for anyone planning an acquisition), Baird chimes in as well, cutting the shares to Neutral from Outperform (price target still $16). (earnings, CC) Comment! [Healthcare, On the Move]
-
Friday, May 10, 12:52 PM
Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%. Comment! [On the Move] - Friday, May 10, 9:39 AM More on Optimer's (OPTR -8.2%) Q1 results: Dificid net sales of $16.8M versus $14.4M in Q1 2012. The company sees a 5% increase in demand for the product but Needham's Alan Carr notes that consensus estimates were for Dificid sales of $20M and worries that the "concerning" sales trajectory (0% growth Q/Q) could reduce the premium any potential suitor might be willing to pay to acquire the company. (PR) Comment! [Healthcare, On the Move]
-
Friday, May 10, 9:10 AM
Premarket gainers: PGNX +26%. UNIS +21%. UBNT +19%. SQNM +11%. MCP +11%. XIN +7%. NBG +6%. NTE +5%. MT +5%.
Losers: PTIE -48%. IFMI -36%. AFFY -18%. SNTS -7%. OPTR -7%. DDD -6%. MDRX -6%. LFVN -5%. Comment! [On the Move] - Tuesday, April 2, 10:02 AM Optimer Pharmaceuticals (OPTR) surges 18.1% following a report that the antibiotics maker has attracted takeover interest from GlaxoSmithKline (GSK), AstraZeneca (AZN), Cubist Pharmaceuticals (CBST) and Japan's Astellas. Optimer hopes to fetch up to $1B in an auction, well above its market cap of $660M. The company has one drug on the market, Dificid, which is used to treat intestinal infections in hospitalized patients. 1 Comment [Healthcare, On the Move]
-
Wednesday, February 27, 12:55 PM
Midday top 10 gainers: ZGNX +39%. UNXL +24%. FSGI +21%. GWRE +18%. ELMD +16%. PDCE +14%. OPTR +13%. DLTR +12%. END +11%. SHI +11%.
Midday top 10 losers: AH -26%. CBB -23%. AMBO -22%. RNIN -21%. CBMX -19%. XWES -19%. FSLR -16%. CMGE -15%. CRMB -13%. PRPH -12%. Comment! [On the Move] - Wednesday, February 27, 10:31 AM Optimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range of strategic alternatives and has engaged JPMorgan and Centerview Partners as financial advisers. The board stated however, that there are no assurances that the review will result in any action and that there would be no further comment on the process until it's completed. The company also preannounced Q4 results of $0.02 per share, and appointed its chairman, Dr. Henry McKinnell, as CEO. Comment! [Healthcare, Earnings, On the Move]
-
Friday, January 4, 5:50 PM
After-hours top gainers, as of 5:15 p.m.: OPTR +16%. GTI +9%. DSLV +3%. EGLE +2%. GNMK +2%.
After-hours top losers: MSPD -8%. CFFN -5%. G -4%. PL -4%. WCRX -2%. Comment! [On the Move] - Tuesday, July 31, 2012, 5:43 PM Optimer Pharma (OPTR): Q2 EPS of -$0.01 beats by $0.06. Revenue of $49.8M (+150809.1% Y/Y) beats by $0.33M. Shares -4.8% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
-
Monday, April 9, 2012, 9:05 AM
Premarket gainers: AOL +35%. GOLD +7%. SCLN +4%.
Losers: MOH -22%. HOGS -11%. OPTR -5%. RDN -4%. AVP -4%. ALU -4%. DRYS -3%. S -3%. X -3%. Comment! [On the Move] - Monday, April 9, 2012, 7:55 AM Shares of Optimer Pharmaceuticals (OPTR) come off their trading halt down 4.7% premarket after the firm cleans house and warns that Q1 revenue will be lower than the estimates of analysts. Comment! [On the Move, Healthcare]
- Wednesday, September 21, 2011, 12:23 PM Optimer Pharmaceuticals (OPTR +3.8%) trades up after BMC initiates the shares with a buy. The firm says the company's newly launched antibiotic, Dificid, will exceed sales expectations in both the near and longer term. Comment! [Healthcare, On the Move, Quick Ideas]
- Monday, September 19, 2011, 2:34 PM Optimer Pharmaceuticals (OPTR) is up 6.4% after Jefferies reiterates a Buy and $17 PT. The firm is bullish on better-than-expected sales of Optimer's Dificid drug, and on the pending EU launch of the drug by partner Astellas (ALPMY.PK). Jefferies also thinks milestone payment from Astellas will strengthen Optimer's cash position. Comment! [Healthcare, On the Move, Quick Ideas]
-
Tuesday, May 31, 2011, 9:00 AM
Premarket gainers: YONG +50%. FCEL +14%. NBG +10%. LDK +6%. OPTR +6%. AEZS +7%. SPIL +5%. RDN +5%. BPAX +4%. NDCO +4%. LOGI +4%. PAL +4%. FSLR +4%. ASH +4%.
Losers: NOK -11%. IRE -6%. ARNA -4%. Comment! [On the Move]
-
Ryan Mallory
Fuinhaz Setups for February 27 2013 | $BBRY $CCUR $DLTR $OPTR $ZAGG http://bit.ly/YXtYkH - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
LifeSci Advisors
OPTR - I just posted a survey of physicians on their expected use of DIFICID on my website: http://bit.ly/nEORWJ/ - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES